Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer. [electronic resource]
Producer: 20170424Description: 2336-42 p. digitalISSN:- 1097-0215
- Ado-Trastuzumab Emtansine
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor
- Breast Neoplasms -- drug therapy
- Capecitabine -- administration & dosage
- Class I Phosphatidylinositol 3-Kinases
- Female
- Humans
- Kaplan-Meier Estimate
- Lapatinib
- Maytansine -- analogs & derivatives
- Phosphatidylinositol 3-Kinases -- metabolism
- Quinazolines -- administration & dosage
- Receptor, ErbB-2 -- metabolism
- Trastuzumab
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.